Biologics Contract Development Market to Grow with a CAGR of 7.22% through 2029
Increasing outsourcing
to enhance efficiency is expected to drive the Global Biologics Contract
Development Market growth in the forecast period, 2025-2029
According to
TechSci Research report, “Biologics Contract Development Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2029”, the Global Biologics Contract Development Market stood at USD 7.12
billion in 2023 and is anticipated to grow with a CAGR of 7.22% in the forecast
period, 2025-2029. One of the primary drivers propelling the Global Biologics
Contract Development Market is the escalating demand for biopharmaceuticals.
Biologics, which encompass a diverse range of therapeutic proteins, monoclonal
antibodies, vaccines, and gene therapies, have become instrumental in treating
various diseases, including cancer, autoimmune disorders, and infectious
diseases. The inherent complexity of biologics necessitates specialized
expertise in their development, making CDOs invaluable partners for
biopharmaceutical companies seeking to capitalize on this growing demand.
The continuous
advancements in biotechnology play a pivotal role in driving the demand for biology
and, consequently, the need for specialized contract development services.
Innovations in cell culture systems, gene editing technologies, and analytical
tools have enhanced the efficiency, scalability, and precision of biologics
development and production. CDOs at the forefront of adopting and implementing
these technologies are well-positioned to offer cutting-edge solutions to
biopharmaceutical companies, contributing to the overall growth of the market.
Biopharmaceutical companies are increasingly turning to outsourcing as a
strategic approach to enhance efficiency and focus on core competencies.
Outsourcing key aspects of biologics development to CDOs allows companies to
leverage the specialized knowledge and infrastructure of these organizations.
This, in turn, accelerates the drug development process, reduces
time-to-market, and optimizes resource allocation for pharmaceutical companies.
The intricate
nature of biologics development, involving sophisticated processes such as cell
line development, process optimization, and analytical testing, contributes to
the rising reliance on CDOs. These organizations are equipped with the
expertise and capabilities required to navigate the complexities inherent in
biologics development, ensuring the successful progression of therapeutic
candidates from early stages to commercialization.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Biologics Contract Development Market”
The Global Biologics
Contract Development Market is segmented into Source, Services, Indication,
Regional Distribution, And Company
Based on the
Source, Mammalian emerged as the dominant segment in the Global Biologics
Contract Development market in 2023. This
is on account the intricate nature of therapeutic proteins and monoclonal
antibodies requiring mammalian cells for proper folding and post-translational
modifications. The demand for complex biologics, aligned with the capabilities
of mammalian expression systems, especially Chinese hamster ovary (CHO) cells,
propelled their widespread usage, contributing to the segment's prominence in
meeting the industry's evolving requirements. Mammalian expression systems offer numerous benefits for
manufacturing intricate biologics, including monoclonal antibodies and
therapeutic proteins. These systems leverage mammalian cells, providing
essential cellular machinery for precise folding, assembly, and
post-translational modifications. This ensures the biologics closely mirror
those in the human body, minimizing immunogenicity risks and enhancing
therapeutic efficacy and safety. The heightened demand for mammalian cell
expression systems stems from the growing complexity of biologics, especially
those necessitating precise glycosylation patterns. Additionally, mammalian
cells are favored for biologics intended for human use, producing proteins with
fitting structures and functions.
Based
on the Services , process development services emerged as the dominant segment
in the Global Biologics Contract
Development Market in 2023. This is due
to the pivotal role process development services play in optimizing
manufacturing processes for biologics. As the demand for efficient and scalable
production of biopharmaceuticals rises, the emphasis on refining processes
becomes paramount. Process development services, encompassing fermentation,
purification, and formulation optimization, are instrumental in establishing
robust and cost-effective procedures. Biologics process development encompasses
two distinct yet interconnected techniques: upstream process development and
downstream process development. The dominance of this segment reflects the
industry's recognition of the critical role played by process development in
ensuring the quality, efficiency, and scalability of biologics manufacturing.
North
America emerged as the dominant player in the Global Biologics Contract
Development Market in 2023, holding the largest market share. North America,
particularly the United States, has traditionally been a major hub for
biopharmaceutical research, development, and manufacturing. The region hosts
numerous biotechnology and pharmaceutical companies, research institutions, and
contract development organizations (CDOs) specializing in biologics. The United
States, in particular, is home to a significant concentration of
biopharmaceutical companies and CDOs. This concentration fosters a
collaborative ecosystem that drives innovation and expertise in biologics
development. North America leads in biopharmaceutical research and development,
with a robust pipeline of biologics in various stages of development. This
innovation contributes to the demand for contract development services.
Major companies
operating in Global Biologics Contract Development Market are:
- WuXi Biologics
- Abzena Ltd
- Fujifilm Diosynth Biotechnologies
- KBI Biopharma
- AGC Biologics
- Thermo Fisher Scientific Inc.
- Curia Global, Inc.
- Genscript
- Bionova Scientific, Inc.
- BioXcellence (Boehringer Ingelheim
Biopharmaceuticals GmbH)
Download Free Sample Report
Customers can
also request for 10% free customization
on this report
“The
Global Biologics Contract Development Market is poised for robust growth in the
coming years. The rising prevalence of complex diseases and a growing understanding
of molecular pathways have heightened the demand for innovative biologics,
including monoclonal antibodies, gene therapies, and personalized medicines. As
pharmaceutical and biotechnology companies seek to expedite the development of
these advanced therapies, the outsourcing of biologics contract development
services is becoming pivotal. The market is witnessing heightened activity in
cell line development, process optimization, and analytical testing, reflecting
the industry's commitment to ensuring efficient and high-quality biologic
production. Additionally, the global push towards personalized medicine and the
expansion of biosimilars are further propelling the demand for specialized
expertise offered by contract development organizations.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Biologics
Contract Development Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2019-2029 Segmented By Source (Mammalian, Microbial, Others), By
Service (Cell Line Development, Process Development, Others), By Indication
(Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological
Disorders, Others) Region and Competition”, has evaluated
the future growth potential of Global Biologics Contract Development Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers, challenges,
and opportunities in Global Biologics Contract Development Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com